Yesterday, MHP announced yet another long-term operating deal for a hotel in the upper up-scale segm...
Enea's Q2 came in line: net sales +1% and adj. EBITDA +3% vs Redeye's estimate, with full-year guida...
* Adj. EBITA 1% vs cons, -2% vs ABGSCe, up 3% y-o-y * Continued margin increase, and org.
Redeye provides its first take on Camurus’ Q2 report 2026, published this morning.
Redeye comments on Hexatronic's Q2 2026 report, which showed a broad-based beat driven chiefly by a ...
L&T announced a profit warning for FY 2026 and pre-released H1 numbers, reflecting continued high di...
Redeye retains its positive view of Lime following the solid Q2, with ARR as expected and strong Exp...
Redeye retains its positive view of Vitec following a solid Q2 report, showing underlying sales roug...
* Sales SEK 60m (+9% vs. ABGSCe), first EBIT-positive quarter * We continue to forecast full-year pr...
Duni reported weaker numbers than our estimates and we expect disruptions to continue into next quar...
Prisma visar fortsatt underliggande styrka trots hög expansionstakt.
VNV reported a Q2 NAV per share of SEK 35, up 2% q/q in SEK terms.
* Record quarterly sales: SEK 60m (+11% y-o-y), +9% vs.
* Q2 report broadly in line with expectations * The Bridge deal is the largest incremental news * Si...
Duni Q2/26 came in below our estimate, with organic growth of -3% in line, but operating income of S...
Bactiguard’s Q2 net sales of SEK 54m came in +11% vs SEB (SEK 49m).
* CRL questions SPARKLE endpoint analysis; re-read rejected *Ascelia disputes both points; expresses...
* Q2'26 numbers due on 22 July at 07:45 CET * Minor estimate changes, margins unchanged * Fair value...
Redeye takes a positive view on 4C's Q2 report, which delivered a stronger-than-expected topline alo...
SynAct Pharma has reported that some early preclinical data have shown that resomelagon may reduce i...
